Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
| Brand name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Generic name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE |
| Distributed by / for | Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 |
| NDC | 0093-3241-01 |
| Full product label | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE TABLETS 2.5 mg/6.25 mg, 100-count bottles, Rx Only, Distributed by: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-3241-01 RX; TABLETS |
| Recalling firm | Cardinal Health Inc. |
| Distribution | FL, GA, SC |
| Quantity | 235 bottles |
| Recall initiated | 2021-03-15 |
| Report date | 2021-06-02 |
| Recall completed | 2024-06-17 |
| Recall number | D-0575-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗